M Sloan Kettering
The 65-year-old man fired five or six shots inside Memorial Sloan Kettering’s urgent care facility on East 67th Street at about 8:45 p.m., law enforcement sources said. The man, who was released. Every gift matters in the fight against cancer. Your generous gift will help support cutting-edge research, world-class cancer care for patients and their families, and vital education programs to train the next generation of cancer specialists.
NEW YORK - Police say an armed man who barricaded himself inside the Memorial Sloan Kettering Cancer Center on the Upper East Side on Thursday night has been arrested and charged.
Officers responded to a 911 call at the center’s urgent care treatment center shortly before 10 p.m.
Police say the man, identified as Joseph Gill, 65, was barricaded inside and is believed to be a cancer patient.
Sloan Kettering Careers
He is charged with two counts of attempted murder for firing several shots at police officers.
He was also charged with criminal possession of a loaded firearm.
No injuries had been reported as of midnight Thursday.
The New York City-based Memorial Sloan Kettering Cancer Center has launched an Innovation Hub (iHub), designed to provide a focused avenue for healthcare innovators to partner with MSK to accelerate the development of their products and business.
From startups to leading global corporations, partners are essential to the iHub’s mission to lead the world in shaping the future of cancer care and prevention, leaders of the organization contend. To deliver on that mission, MSK has selected the following investment areas for this year:
- Digital therapeutics - digital solutions that deliver evidence-based therapeutic interventions to prevent, manage, or treat cancer-related healthcare conditions, with a focus on prevention, screening, adherence, pain management and mental health
- AI enabled computational oncology – solutions that use computational models to improve tumor classification and treatment planning, define tumor progression, and identify predictive biomarkers using a combination of genomic, clinical, and radiological data
- Population insights - solutions for early detection and diagnosis, screening, risk stratification, and high-risk surveillance and monitoring, using relevant clinical, genomic and environmental data
- Remote patient monitoring - technologies that enable patient monitoring outside of conventional care settings to manage, evaluate, notify, and modify treatment plans
MSK officials note that the organization works closely with its partners to accelerate the development and commercialization of innovative healthcare solutions in exchange for a stake in the commercialization outcome. iHub collaborations are anchored on the partner company’s product/IP, where MSK may provide iHub partners with unique acceleration capabilities including:
- Clinical intelligence: Inform product design and development, as well as clinical study design, by working with leading subject matter experts
- Market intelligence: Access to MSK leadership teams and their unique knowledge of healthcare industry
- Product development: Leverage select MSK resources to support product development and commercialization, including generating meaningful data and evidence for solutions through clinical studies
- Marketing: Support go-to-market strategy
M Sloan Kettering Hospital
To apply to the MSK iHub, candidates can fill out the initial application form. Solutions that are most relevant to the investment areas will be asked to fill out the full application form, which will be reviewed by the MSK leadership team, and select industry experts. The initial form opens to the public on Oct. 15, and by Nov. 13, the MSK iHub leadership team will select candidates to move on to full application stage.
